CIK 0000899923 · Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 870494517
- Phone
- 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-01 | Solaiman Shereen Chief People Officer | Shares withheld for taxes | −1,912 | $10.73 | $21K | 53,878 |
| 2025-02-25 | Haas Kevin Richard Chief Technology Officer | Shares withheld for taxes | −1,016 | $11.74 | $12K | 128,566 |
| 2025-02-25 | Ancona Margaret SVP, Chief of Staff | Shares withheld for taxes | −2,697 | $11.74 | $32K | 75,703 |
| 2025-02-07 | Munk Natalie Chief Accounting Officer | Grant or award | +3,316 | 46,575 | ||
| 2025-02-07 | Ancona Margaret SVP, Chief of Staff | Grant or award | +6,468 | 82,171 | ||
| 2025-02-07 | Haas Kevin Richard Chief Technology Officer | Grant or award | +12,758 | 141,324 | ||
| 2025-02-07 | Muzzey Dale Chief Scientific Officer | Grant or award | +10,622 | 117,766 | ||
| 2025-02-07 | Verratti Mark Chief Commercial Officer | Grant or award | +12,758 | 302,035 | ||
| 2025-02-07 | DIAZ PAUL J President and CEO | Grant or award | +114,828 | 1,077,206 | ||
| 2025-01-29 | Leffler Scott J. Chief Financial Officer | Shares withheld for taxes | −12,230 | $12.54 | $153K | 152,445 |
| 2025-01-01 | Muzzey Dale Chief Scientific Officer | Shares withheld for taxes | −417 | $13.71 | $6K | 107,144 |
| 2024-12-11 | Raha Samraat S. Chief Operating Officer | Shares withheld for taxes | −29,578 | $14.51 | $429K | 272,394 |
| 2024-12-10 | Davis Mark Steven Director | Grant or award | +22,816 | 22,816 | ||
| 2024-11-30 | Raha Samraat S. Chief Operating Officer | Grant or award | +1,118 | $13.83 | $15K | 301,972 |
| 2024-10-11 | DIAZ PAUL J President and CEO | Sale 10b5-1 | −15,000 | $22.93 | $344K | 962,378 |
| 2024-10-09 | Muzzey Dale Chief Scientific Officer | Shares withheld for taxes | −452 | $24.37 | $11K | 107,561 |
| 2024-10-09 | Haas Kevin Richard Chief Technology Officer | Shares withheld for taxes | −2,515 | $24.37 | $61K | 129,582 |
| 2024-10-09 | Verratti Mark Chief Commercial Officer | Shares withheld for taxes | −3,359 | $24.37 | $82K | 294,281 |
| 2024-10-09 | Verratti Mark Chief Commercial Officer | Shares withheld for taxes | −5,004 | $24.37 | $122K | 289,277 |
| 2024-09-21 | Munk Natalie Chief Accounting Officer | Shares withheld for taxes | −964 | $27.64 | $27K | 43,259 |
Page 8 of 15 · 286 trades